Executive Summary
This digest covers a single $57.3 million civilian contract from the Department of Health and Human Services (HHS) to Harvard College, a non-profit educational institution, for tuberculosis immunity research under NIH/NIAID. The award is cost-no-fee, generating zero profit for the recipient, and carries a neutral signal strength of 1/10 with no defense-related exposure.
The dominant theme is steady, non-commercial NIH funding for infectious disease research, which is immaterial to public equity investors. Key risk: this contract displaces no for-profit competitors and offers no direct investment catalyst. The aggregate total obligation is $57,273,777, with zero defense contracts and zero bullish or bearish signals identified.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from July 10, 2026.
Investment Signals (1)
- Harvard College Receives $57.3M Cost-No-Fee NIH R&D Contract for TB Research (HIGH)▲
Harvard College secured a $57.3 million cost-no-fee R&D contract from NIH/NIAID for tuberculosis immunity research (IMPAC-TB), with a base-plus-options ceiling of $59.8 million through March 2027. As a non-profit, Harvard generates no profit, making this irrelevant for equity investors in public companies.
Risk Flags (1)
- Concentration [LOW RISK]▼
Single contract to a non-profit educational institution with zero profit margin; no for-profit companies are involved, creating no competitive displacement risk for public biotech or defense contractors.
Opportunities (1)
- ◆
Steady NIH funding for infectious disease R&D, but this specific award is non-commercial and does not create growth opportunities for public companies.
Sector Themes (1)
- ◆
The $57.3 million award to Harvard College for TB immunity research is a cost-no-fee contract with no profit, demonstrating that large NIH grants to academic institutions do not translate into revenue or earnings for publicly traded companies.
Watch List (1)
- 👁
{"entity" => "None", "reason" => "No public companies are involved; contract is immaterial to equity investors.", "trigger" => "None"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: HHS & Healthcare Contracts Intelligence
🇺🇸 More from United States
View all →July 23, 2026
US Pre-Market SEC Filings Roundup — July 23, 2026
US Pre-Market SEC Filings Roundup
July 23, 2026
USA Corporate Events Calendar — July 23, 2026
USA Corporate Events Calendar
July 23, 2026
USA Earnings Calls Schedule — July 23, 2026
USA Earnings Calls Schedule
July 23, 2026
Mega Contracts Monitor ($100M+) — July 23, 2026
Mega Contracts Monitor ($100M+)